SCHEMBL6484696

SCHEMBL6484696

CCC(C)(C)C[C@H](NC(=O)c1cc[nH]c1)C(=O)NC1C(=O)COC1CCN(C)C

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSL P07711 20/20 0.51
CTSS P25774 20/20 0.51
CTSK P43235 20/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477007 0.93 CTSL (0.57) CTSLCTSSCTSK
SCHEMBL6484503 0.91 CTSL (0.61) CTSLCTSSCTSK
SCHEMBL6475188 0.90 CTSL (0.49) CTSLCTSSCTSK
SCHEMBL6476923 0.90 CTSL (0.46) CTSLCTSSCTSK
SCHEMBL6485411 0.89 CTSL (0.45) CTSLCTSSCTSK
SCHEMBL6475015 0.88 CTSK (0.54) CTSLCTSSCTSK
SCHEMBL6475006 0.88 CTSL (0.47) CTSLCTSSCTSK
SCHEMBL6484425 0.87 CTSL (0.52) CTSLCTSSCTSK
SCHEMBL6485668 0.86 CTSK (0.43) CTSLCTSSCTSK
SCHEMBL6486756 0.85 CTSL (0.49) CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050020588-A1 Cysteine protease inhibitors PEPTIMMUNE, INC. 2005-01-27 US claimed
JP-2002544274-A 2002-12-24 JP claimed
EP-1178986-A2 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S Medivir UK Ltd (GB) 2002-02-13 EP claimed
WO-2000069855-A2 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S MEDIVIR UK LIMITED (GB) 2000-11-23 WO claimed
US-20050020588-A1 Cysteine protease inhibitors PEPTIMMUNE, INC. 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020588-A1 Cysteine protease inhibitors CTSS, CTSE, CTSV CTSL 11/4885CTSS 1/4885CTSK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.